The Perfect Prescription? Why J&J Can Gain 16%

Jefferies analyst Jeffrey Holford upgraded Johnson & Johnson to a Buy, arguing that the Street underestimates how much the health-care conglomerate can profit from its pharmaceutical division. 
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>